Pharmacokinetic interaction between telaprevir and methadone

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2304-2309

  Van Heeswijk, Rolf ^a   Verboven, Peter ^b   Vandevoorde, Ann ^a   Vinck, Petra ^b   Snoeys, Jan ^b   Boogaerts, Griet ^a   De Paepe, Els ^a   Van Solingen Ristea, Rodica ^c   Witek, James ^c   Garg, Varun ^d  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; TELAPREVIR;

ADULT; ARTICLE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; EUPHORIA; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; OLIGOPEPTIDES; OPIATE SUBSTITUTION TREATMENT; STEREOISOMERISM; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84876235946     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02262-12     Document Type: Article

References (21)

1. Pouget ER, Hagan H, Des Jarlais DC. 2012. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction 107:1057-1065.
2. Novick DM, Kreek MJ. 2008. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance therapy. Addiction 103:905-918.
3. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, Study Team ADVANCE. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364:2405-2416.
4. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F, Study Team ILLUMINATE. 2011. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365:1014-1024. (Erratum, 365:1551.)
5. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, Study Team REALIZE. 2011. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364:2417-2428.
6. Jage J. 1989. Methadone: pharmacokinetics and pharmacodynamics of an opiate. Anaesthesist 38:159-166.
7. Eap CB, Bourquin M, Martin J, Spagnoli J, Livoti S, Powell K, Baumann P, Déglon J. 2000. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend. 61:47-54.
8. Ansermot N, Albayrak O, Schläpfer J, Crettol S, Croquette-Krokar M, Bourquin M, Déglon JJ, Faouzi M, Scherbaum N, Eap CB. 2010. Substitution of (R,S)-methadone by (R)-methadone: impact on QTc interval. Arch. Intern. Med. 170:529-536.
9. Mallinckrodt Inc. 2012. Methadose FDA label. http://www.accessdata.fda .gov/drugsatfda-docs/label/2008/017116s021lbl.pdf. Accessed 24 July 2012.
10. Garg V, Chandorkar G, Farmer HF, Smith F, Alves K, van Heeswijk RP. 2012. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J. Clin. Pharmacol. 52:1566-1573.
11. Gossop M. 1990. The development of a short opiate withdrawal scale (SOWS). Addict. Behav. 15:487-490.
12. Franken IA, Hendriksa VM, van de Brink W. 2002. Internal validation of two opiate craving questionnaires: the obsessive compulsive drug use scale and the desires for drug questionaire. Addict. Behav. 27:675-685.
13. Kharasch ED, Bedynek PS, Park S, Whittington D, Walker A, Hoffer C. 2008. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin. Pharmacol. Ther. 84:497-505.
14. Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, Rostami- Hodjegan A. 2008. Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr. Drug Metab. 9:384-393.
15. Vertex Pharmaceuticals Inc. 2012. Incivek U.S. prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/201917lbl.pdf. Accessed 1 November 2012.
16. Garg V, Kauffman RS, Beaumont M, van Heeswijk RP. 2012. Telaprevir: pharmacokinetics and drug interactions. Antivir. Ther. 17:1211-1221.
17. Lehotay DC, George S, Etter ML, Graybiel K, Eichhorst JC, Fern B, Wildenboer W, Selby P, Kapur B. 2005. Free and unbound enantiomers of methadone and its metabolite, EDDP in methadone maintenance treatment; relationship to dosage? Clin. Biochem. 38:1088-1094.
18. Gerber JG, Rosenkranz S, Segal Y, Aberg J, D'Amico R, Mildvan D, Gulick R, Hughes V, Flexner C, Aweeka F, Hsu A, Gal J, ACTG 401 Study Team. 2001. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J. Acquir. Immune Defic. Syndr. 27:153-160.
19. Cao YJ, Smith PF, Wire MB, Lou Y, Lancaster CT, Causon RC, Bigelow GE, Martinez E, Fuchs EJ, Radebaugh C, McCabe S, Hendrix CW. 2008. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects. Pharmacotherapy 28:863-874.
20. Romach MK, Piafsky KM, Abel JG, Khouw V, Sellers EM. 1981. Methadone binding to orosomucoid (alpha-acid glycoprotein): determinant of free fraction in plasma. Clin. Pharmacol. Ther. 29:211-217.
21. Benet LZ, Hoener BA. 2002. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 71:115-121.